ORKA
VENTE TOTALE: 75 000 titres (~6 809 010,00 $ US)
- Insiders
- Klein Lawrence Otto
- Total bought
- —
- Total sold
- $6,809,010
- Last activity
- 2026-09-01
- Last synced
-
2026-09-07 10:23:47
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-03
ORKA presents a deeply concerning financial profile with zero revenue, persistent negative cash flows, and a near-failed business model that undermines any catalyst-driven upside.
The first sentence of the analysis written for ORKA on 2026-09-03 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 22.366 | 28.894 | 59.014 | 37.720 | 15.558 | |
| Quick Ratio | 22.366 | 28.894 | 59.014 | 37.720 | 15.558 | |
| Solvency Ratio | -6.313 | -6.066 | -6.216 | -6.949 | -4.955 | |
| Cash Ratio | 3.053 | 4.721 | 58.761 | 37.496 | 15.254 | |
| Price To Earnings Ratio | -13.121 | -3.886 | -4.595 | -3.439 | -1.547 | |
| Price To Earnings Growth Ratio | 0.244 | -0.314 | 0.099 | 0.068 | -0.016 | |
| Forward Price To Earnings Growth Ratio | 0.244 | -0.314 | 0.099 | 0.068 | -0.016 | |
| Price To Earnings Diluted Ratio | -13.121 | -3.886 | -4.595 | -3.439 | -1.547 | |
| Price To Earnings Diluted Growth Ratio | 0.244 | -0.314 | 0.099 | 0.068 | -0.016 | |
| Price To Book Ratio | 2.930 | 0.852 | 7.944 | 9.834 | 7.028 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -15.637 | -5.610 | 0.000 | -37.550 | -19.076 | |
| Price To Operating Cash Flow Ratio | -15.674 | -5.629 | 0.000 | -37.557 | -19.119 | |
| Debt To Assets Ratio | 0.004 | 0.002 | 0.007 | 0.009 | 0.009 | |
| Debt To Equity Ratio | 0.004 | 0.003 | 0.008 | 0.009 | 0.009 | |
| Debt To Capital Ratio | 0.004 | 0.003 | 0.008 | 0.009 | 0.009 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.035 | 1.036 | 1.023 | 1.034 | 1.076 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -5.738 | -4.434 | 0.000 | -9.640 | -5.364 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.002 | 1.003 | 0.000 | 1.000 | 1.002 | |
| Debt Service Coverage Ratio | -170.194 | -48.917 | -68.789 | -95.262 | -192.310 | |
| Interest Coverage Ratio | 0.000 | -60.029 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | -142.504 | -271.535 | 0.000 | -105.942 | -187.620 | |
| Operating Cash Flow Coverage Ratio | -45.657 | -59.749 | 0.000 | -28.491 | -38.845 | |
| Capital Expenditure Coverage Ratio | -422.057 | -306.016 | 0.000 | -5,456.000 | -436.326 | |
| Dividend Paid And Capex Coverage Ratio | -422.057 | -0.178 | 0.000 | -5,456.000 | -436.326 | |
| Dividend Payout Ratio | 0.000 | -3.882 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -12.696 | -3.222 | -49.146 | -37.481 | -15.904 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 22.366 | ▼-6.528 | ▼-10.344 |
| Quick Ratio | 22.366 | ▼-6.528 | ▼-10.344 |
| Solvency Ratio | -6.313 | ▼-0.247 | ▼-0.213 |
| Cash Ratio | 3.053 | ▼-1.668 | ▼-20.804 |
| Price To Earnings Ratio | -13.121 | ▼-9.235 | ▼-7.804 |
| Price To Earnings Growth Ratio | 0.244 | ▲0.558 | ▲0.228 |
| Forward Price To Earnings Growth Ratio | 0.244 | ▲0.558 | ▲0.228 |
| Price To Earnings Diluted Ratio | -13.121 | ▼-9.235 | ▼-7.804 |
| Price To Earnings Diluted Growth Ratio | 0.244 | ▲0.558 | ▲0.228 |
| Price To Book Ratio | 2.930 | ▲2.078 | ▼-2.788 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -15.636 | ▼-10.026 | ▼-0.062 |
| Price To Operating Cash Flow Ratio | -15.674 | ▼-10.045 | ▼-0.078 |
| Debt To Assets Ratio | 0.004 | ▲0.002 | ▼-0.002 |
| Debt To Equity Ratio | 0.004 | ▲0.002 | ▼-0.003 |
| Debt To Capital Ratio | 0.004 | ▲0.002 | ▼-0.002 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.035 | ▼-0.001 | ▼-0.005 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -5.738 | ▼-1.303 | ▼-0.703 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.002 | ▼-0.001 | ▲0.201 |
| Debt Service Coverage Ratio | -170.194 | ▼-121.277 | ▼-55.099 |
| Interest Coverage Ratio | 0.000 | ▲60.029 | ▲12.006 |
| Short Term Operating Cash Flow Coverage Ratio | -142.504 | ▲129.031 | ▼-0.984 |
| Operating Cash Flow Coverage Ratio | -45.657 | ▲14.092 | ▼-11.109 |
| Capital Expenditure Coverage Ratio | -422.057 | ▼-116.041 | ▲902.022 |
| Dividend Paid And Capex Coverage Ratio | -422.057 | ▼-421.880 | ▲840.855 |
| Dividend Payout Ratio | 0.000 | ▲3.881 | ▲0.776 |
| Enterprise Value Multiple | -12.696 | ▼-9.474 | ▲10.993 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.38B | $325.5M | $294.1M | $409.8M | $358.7M | |
| Enterprise value | $1.34B | $264.9M | $256.9M | $367.8M | $305.8M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -15.16x | -4.58x | 0.00x | -33.70x | -16.30x | |
| EV / Free cash flow | -15.13x | -4.57x | 0.00x | -33.70x | -16.26x | |
| EV / EBITDA | -12.70x | -3.22x | -49.15x | -37.48x | -15.90x | |
| Net debt / EBITDA | 0.43x | 0.74x | 7.11x | 4.29x | 2.75x | |
| Current ratio | 22.37x | 28.89x | 59.01x | 37.72x | 15.56x | |
| Income quality | 0.84x | 0.69x | 0.00x | 1.10x | 0.97x | |
| Graham net-net | $7 | $22 | $3 | $3 | $4 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 101.8% | 100.0% | 100.0% | 100.0% | |
| Working capital | $328.5M | $363.8M | $37.0M | $41.6M | $50.9M | |
| Invested capital | $330.6M | $364.9M | $37.2M | $41.9M | $51.4M | |
| Return on assets | -21.6% | -21.1% | -14.1% | -23.0% | -35.2% | |
| Operating ROA | -27.6% | -40.6% | -18.0% | -20.1% | -36.7% | |
| Return on tangible assets | -21.6% | -21.1% | -14.1% | -23.0% | -35.2% | |
| Return on equity | -22.3% | -21.9% | -14.4% | -23.8% | -37.9% | |
| Return on invested capital | -25.8% | -23.0% | -19.6% | -23.4% | -37.5% | |
| Return on capital employed | -25.8% | -23.0% | -19.6% | -23.5% | -37.6% | |
| Earnings yield | -7.6% | -25.7% | -1.8% | -2.4% | -5.4% | |
| Free cash flow yield | -6.4% | -17.8% | 0.0% | -2.7% | -5.2% | |
| Capex / Op. cash flow | -0.2% | -0.3% | 0.0% | -0.0% | -0.2% | |
| Capex / Depreciation | 251.8% | 700.0% | 0.0% | 1.8% | 47.3% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 18272d | 46801d | 0d | 1069d | 4480d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | -18272d | -46801d | 0d | -1069d | -4480d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+324.7%EV / Sales n/aEV / EBITDA ▼-294.1%EV / Op. cash flow ▼-10.583Earnings yield ▲+0.181
Profitability
Return on equity ▼-0.004Return on assets ▼-0.004Return on invested capital ▼-0.028Return on capital employed ▼-0.028Operating ROA ▲+0.130Income quality ▲+0.146Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding ▼-28529.123Operating cycle n/aCash conversion cycle ▲+28529.123Capex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-6.528Net debt / EBITDA ▼-0.310Working capital ▼-35343000.000Invested capital ▼-34263000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+285.4%EV / Sales n/aEV / EBITDA ▲+20.2%EV / Op. cash flow ▲+1.138Earnings yield ▼-0.022
Profitability
Return on equity ▲+0.155Return on assets ▲+0.136Return on invested capital ▲+0.118Return on capital employed ▲+0.118Operating ROA ▲+0.091Income quality ▼-0.134Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding ▲+13791.713Operating cycle n/aCash conversion cycle ▼-13791.713Capex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+6.808Net debt / EBITDA ▼-2.322Working capital ▲+277560000.000Invested capital ▲+279193000.000Intangibles / Total assets n/a
Employee count
No employee-count data synced.
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-28 ORKA Stock Up More Than 60% in 3 Months: Here''s What You Should Know Oruka''s three-month rally reflects investor confidence in ORKA-001, with key clinical data and pipeline milestones scheduled ahead.
- 2026-08-25 BlackRock Inc. Purchases Shares of 4,990,181 Oruka Therapeutics, Inc. $ORKA BlackRock Inc. purchased a new position in Oruka Therapeutics, Inc. (NASDAQ: ORKA) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 4,990,181 shares of the company''s stock, valued at approximately $474,916,000. BlackRock Inc. owned about 8.27% of Oruka
- 2026-08-24 Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer MENLO PARK, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today announced the appointment of Todd Edwards as Chief Commercial Officer, effective August 24, 2026.
- 2026-08-11 4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026 PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.
- 2026-08-10 Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update EVERLAST-A Week 28 data expected at the end of 3Q 2026; 52-week data for all participants expected in December 2026 EVERLAST-B fully enrolled ahead of schedule, with Week 16 data now expected in 4Q 2026 Phase 3 program for ORKA-001 expected to begin in 1H 2027 ORCA-SURGE Week 16 data accelerated, now expected in 1Q 2027 ORCA-SPLASH, a Phase 2 trial of ORKA-002 in moderate-to-severe hidradenitis suppurativa, initiated ORKA-004, a novel half-life extended monoclonal antibody targeting TL1A, to enter the clinic in 4Q 2026 Cash, cash equivalents and marketable securities of $1.1 billion expected to fund the Company through a BLA filing for ORKA-001
- 2026-06-27 Oruka Stock Is Now Up Nearly 700%. Here''s What a $687,000 Insider Sale Could Mean This biotech innovator in monoclonal antibody therapies reported a notable insider sale amid ongoing clinical-stage developments.
- 2026-06-24 Oruka Therapeutics'' Head of Finance Sold Over 10,000 Company Shares. What Does That Mean for Investors? Arjun Agarwal sold 10,290 shares for a transaction value of approximately ~$608,000, based on a weighted average price of $59.07 per share on May 18, 2026. This sale represented 38.5% of Agarwal''s direct holdings, reducing direct ownership from 26,696 to 16,406 shares.
- 2026-06-12 Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock? Oruka Therapeutics, Inc. (ORKA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 2026-06-10 Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here''s is How to Trade The mean of analysts'' price targets for Oruka Therapeutics, Inc. (ORKA) points to an 111.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.